临床试验/ACTRN12621001319864

ACTRN12621001319864招募中未知

Real world management and outcome of melanoma patients in Australasia using the MASTER registry (MASTER: MelanomA data to capture Standard of care Treatment and outcomEs and to support Research)

The Walter and Eliza Hall Institute of Medical Research0 个研究点目标入组 200 人开始时间: 2021年9月28日最近更新: 2022年9月5日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方: The Walter and Eliza Hall Institute of Medical Research
入组人数: 200

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•1. Patient with stage III or IV cutaneous or unknown primary melanoma
•2. Aged 18 years or above at diagnosis

排除标准

未提供

研究者

发起方

The Walter and Eliza Hall Institute of Medical Research

相似试验

进行中（未招募）

Treatment of patients with metastatic melanoma with TadalafilPreviously treated metastatic melanoma in stage IV or III unresectableMedDRA version: 14.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-003273-28-DERuprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D12

Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil:A Pilot Trial for Proof of Principle”

DRKS00003495niversitätsklinikum Heidelberg12

Quality of life research among melanoma patients that have been treated with immunotherapy, or targeted therapy and/or surgeryKwaliteit van LevenQuality of Life10040900

NL-OMON55207Antoni van Leeuwenhoek Ziekenhuis700

Melanoma patients and Quality of Life after active treatmentMelanoma (stage III/IV)

NL-OMON26948o sponsors, the study is investigator initiated500

进行中（未招募）

Kojic Acid Serum and Microneedling in the treatment of MelasmaMelanoseC17.800.621.430

RBR-7kxf2k4Faculdade de Farmácia da Universidade Federal do Rio de Janeiro